Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) is now up 68.63% compared to a 12-month low of $2.55. We have seen the price to move -7.53% lower and get settled at $4.3 on 11/15/2017. At recent session, it appeared stuck in a range of $4.25 to $4.75. This company shares are 128.6% off its target price of $9.83 and the current market capitalization stands at $133.43M. The recent change has given its price a -16.96% deficit over SMA 50 and -33.33% deficit over its 52-week high. The stock witnessed -13.13% declines, -5.49% declines and 14.67% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ADMP’s volatility during a week at 8.01% and during a month it has been found around 6.31%.Adamis Pharmaceuticals Corporation (ADMP) Top Holders
Institutional investors currently hold around $26 million or 16% in ADMP stock. Look at its top three institutional owners. Sio Capital Management, Llc owns $9 million in Adamis Pharmaceuticals Corporation, which represents roughly 6.75% of the company’s market cap and approximately 34.62% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 1,132,029 shares of the stock are valued at $5.26 million. The third largest holder is Eam Investors, Llc, which currently holds $1.73 million worth of this stock and that ownership represents nearly 1.3% of its market capitalization.Adamis Pharmaceuticals Corporation 13F Filings
At the end of 09/30/2017 reporting period, 24 institutional holders increased their position in Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) by some 3,166,265 shares, 21 decreased positions by 658,049 and 6 held positions by 1,742,237. That puts total institutional holdings at 5,566,551 shares, according to SEC filings. The stock grabbed 6 new institutional investments totaling 430,901 shares while 8 institutional investors sold out their entire positions totaling 488,775 shares.Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Insider Trades
Multiple company employees have indulged in significant insider trading. Adamis Pharmaceuticals Corporation disclosed in a document filed with the US Securities and Exchange Commission (SEC) that SR. VP of Corporate Devel. Marguglio David J. has sold 700 shares of Adamis Pharmaceuticals Corporation (ADMP) in trading session dated Jun. 02, 2016. These shares are worth $6,300 and were traded at $9 each. The SEC filing shows that Marguglio David J. performed a sale of 4,000 shares. The SR VP OF CORPORATE DEVELOPMENT disposed these shares by way of transaction on May. 16, 2016. The company’s shares were given away at $8.08 per share worth to an income of some $32,320 on account of Marguglio David J..
SR VP OF CORPORATE DEVELOPMENT, Marguglio David J., sold 6,000 common shares of Adamis Pharmaceuticals Corporation (ADMP) in the open market. In a transaction dated May. 09, 2016, the shares were put up for sale at an average price of $10, raking in a sum of $60,000. After this sale, 106,227 common shares of ADMP are directly owned by the insider, with total stake valued at $456,776.
In the transaction dated May. 09, 2016, the great number of shares disposed came courtesy the SR VP of Corporate Development; Marguglio David J. disposed a total of 4,860 shares at an average price of $10, amounting to approximately $48,600. The insider now directly owns 106,227 shares worth $456,776.Adamis Pharmaceuticals Corporation (ADMP) Analyst Guide
Several analysts have released their opinion on Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), with 2 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.33 average brokerage recommendation.